ResMed Inc. RMD · NYSE
$238.97 -1.35% (-$3.27)
Summary
88 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 27 USD is left as net profit.
- Earnings per share grew by 20% a year over the last 3 years.
- It has raised its dividend 13 years in a row and pays out only 23% of profit.
- It earns 19 USD a year on every 100 USD of invested capital.
What to watch
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 23.1 USD for 1 USD of yearly profit. Over the last five years it was 29.8 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it grew by 10% a year. For the next fiscal year analysts expect revenue to grow by 2.8%. Earnings per share grew by 20% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 39 USD
- Research and development 6.7 USD
- Sales and administration 21 USD
- Taxes and other 6.5 USD
- Net profit 27 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.5 USD
Out of every 100 USD of revenue, 27 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.02%
- Paid out of profit
- 23%
- Raised in a row
- 13 years
You receive $2.46 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Neutral- Buy 14
- Hold 16
- Sell 5
Today's price within the analysts' price targets
The average target of $242.7 is 1.6% above today's price. 40% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Sleep And Respiratory 88%
- Software As Service 12%
By region
- U [S] 64%
- Global 36%
Sleep And Respiratory brings in 88% of revenue. Software As Service grew fastest, by 13% a year.
Segments in detail